argenx (NASDAQ:ARGX) reported positive topline results from its Phase 3 ALKIVIA trial of VYVGART Hytrulo in adults with autoimmune myositis, with the study meeting its primary endpoint in the combined immune-mediated necrotizing myopathy (IMNM) and dermatomyositis (DM) population.
The Phase 3 ALKIVIA trial produced a statistically significant 15.4-point treatment advantage over placebo in mean Total Improvement Score at Week 52, while separate results in IMNM marked the first Phase 3 study to demonstrate statistically significant and clinically meaningful disease-activity improvement in a subtype with no approved therapy.
Key Investor Takeaways
- argenx (NASDAQ:ARGX) said ALKIVIA met its primary endpoint with a 15.4-point greater mean TIS improvement for efgartigimod versus placebo at Week 52, with p=0.0011.
- The treatment benefit emerged from Week 4 and was sustained through one year despite a protocol-mandated corticosteroid taper.
- IMNM patients achieved a statistically significant 14.8-point advantage over placebo, potentially strengthening the case for efgartigimod in a disease subtype with no approved therapy.
- DM patients showed a similar 14.5-point treatment difference, although the smaller cohort did not achieve statistical significance, with p=0.1093.
- Efgartigimod was well tolerated, with its safety profile consistent with previous studies and its established safety profile.
Why ARGX Stock Is in Focus
The primary analysis combined patients with IMNM and DM. At Week 52, patients receiving efgartigimod recorded a mean TIS of 47.95 compared with 32.56 for placebo, producing a 15.4-point difference and a statistically significant result of p=0.0011.
The treatment effect appeared relatively early. According to argenx, improvements over placebo were evident from Week 4 and remained statistically significant through the full year of treatment, even as patients underwent corticosteroid tapering.
Prespecified subtype analysis provided an important distinction between the two patient groups. In IMNM, efgartigimod achieved a mean TIS of 45.05 compared with 30.24 for placebo, a 14.8-point advantage with p=0.0048.
In DM, the treatment produced a 14.5-point advantage, with mean TIS reaching 51.51 versus 36.96 for placebo. That result was considered clinically meaningful by the company but did not achieve statistical significance, with p=0.1093.
All six measures contributing to TIS favoured efgartigimod over placebo across IMNM and DM, covering muscle strength, physical function and disease activity outside the muscle. Improvement in skin disease activity was also observed among DM patients.
Why This Matters for Investors
The IMNM findings may be particularly significant for the development programme because argenx said there is currently no approved therapy for the subtype. The company described ALKIVIA as the first Phase 3 trial to produce statistically significant and clinically meaningful improvements in disease activity for these patients.
The results could also support argenx’s strategy of expanding efgartigimod into additional autoimmune diseases beyond its existing indications. The drug targets FcRn to reduce circulating IgG antibodies, including pathogenic autoantibodies implicated in autoimmune myositis.
Importantly, the similar magnitude of improvement reported across the IMNM and DM cohorts suggests treatment activity was not confined to one subtype. However, investors may distinguish between the statistically significant IMNM outcome and the DM result, which did not cross the threshold for statistical significance in its smaller cohort.
Safety provides another relevant component of the topline readout. argenx reported that efgartigimod was well tolerated and that the safety findings were consistent with previous studies and the drug’s known profile.
ALKIVIA enrolled 264 patients overall, with 175 participating in the Phase 3 portion. The trial evaluated weekly subcutaneous efgartigimod or placebo in patients receiving background treatment.
What to Watch Next
Detailed ALKIVIA data are expected to be presented at an upcoming medical meeting, providing investors with a more complete view of efficacy, safety and outcomes across the individual autoimmune myositis subtypes.
Further development decisions following the positive Phase 3 results will also be important, particularly for IMNM given the absence of an approved therapy cited by argenx.
Beyond myositis, efgartigimod remains under evaluation in other autoimmune rheumatologic diseases, including Sjögren’s disease and systemic sclerosis, making the ALKIVIA outcome relevant to the broader expansion strategy for the FcRn-targeting franchise.